acute urticaria
Conditions
Interventions
Intravenous H1-receptor antagonist (Chlorpheniramine Maleate)
Glycyrrhizic Acid injestion
Sponsors
Yuzawa Community Medical Center
Tsukuba Medical Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are newly diagnosed as an acute moderate or severe urticaria (defined by Japanese guideline); who has had no acute urticaria in 1 month before entry; and no condition requiring emergency management.
Exclusion criteria
Exclusion criteria: Patients who are unreliable in following physicians' directives; did not use of any other H1-receptor antagonists, steroids, or antiallergy agent within 48 hours before entry; have no history of contraindication of H1-receptor antagonist, Glycyrrhizic Acid injestion, or similar articles; are pregnant or in lactation period; have to drive back home by oneself; and are in other conditions at the discretion of the individual physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A visual analog scale (VAS) for pruritus as a patient's subjective measurement | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the itch based on a new rating scale (a 'itch score'), a final global improvement rating | — |
Countries
Japan
Contacts
Public ContactHiromi Watanabe
Yuzawa Community Medical Center Community and family medicine
Outcome results
None listed